Inferra AIResearch Tools

Inferra AI / Company / BMY

Bristol Myers Squibb

BMY · Health Care

Last earnings Oct 29, 2026

Key results

Revenuequarter

3%

revenues increased 3% (+2% Ex-FX) to $12.2 billion

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Total revenuequarter

$12,222

FX** Total Revenues $12,222 $11,892 3 % 2 % Earnings (Loss) Per Share - GAAP* 1.08 0.60 81 % N A Earnings (Loss) Per Share - Non-GAAP* 1.63 1.80 (9) % N A Acquired IPRD Charges and Licensing Income Net Impact on Earnings (Loss) Per Share (0.20) (0.09) N A N A *GAAP and Non-GAAP earnings (loss) per share include the net impact of Acquired IPRD charges and licensing income.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

EPSquarter

81 %

FX** Total Revenues $12,222 $11,892 3 % 2 % Earnings (Loss) Per Share - GAAP* 1.08 0.60 81 % N A Earnings (Loss) Per Share - Non-GAAP* 1.63 1.80 (9) % N A Acquired IPRD Charges and Licensing Income Net Impact on Earnings (Loss) Per Share (0.20) (0.09) N A N A *GAAP and Non-GAAP earnings (loss) per share include the net impact of Acquired IPRD charges and licensing income.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Growth Portfolio revenuequarter

$6.9 billion

Growth Portfolio revenues of $6.9 billion increased 18%, or 17% Ex-FX.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Legacy Portfolio revenuequarter

$5.4 billion

Legacy Portfolio revenues of $5.4 billion decreased 12%, or 13% Ex-FX.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Total revenues of $12.2 billion increased 3%, or 2% Ex-FX.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

revenues of $8.3 billion increased 1%.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

International revenuequarter

$3.9 billion

International revenues of $3.9 billion increased 6%, or 3% Ex-FX.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Gross marginquarter

71.9%

Gross margin on a GAAP and non-GAAP basis was 71.9% and 72.9% in 2025, and 75.1% and 76.0% in 2024, respectively, reflecting the change in product mix.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

AI analysis

Q3 2025 · reported Oct 30, 2025

Based on: Earnings release + Q3 2025 deck + parent 8-K + 10-Q — transcript not held

Gross margin · Q3 2025
71.9%
EX-99 · Oct 30, 2025
Total revenue · Q3 2025
$12,222
-100.0% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025
Growth Portfolio revenue · Q3 2025
$6.9B
+4.5% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025
Legacy Portfolio revenue · Q3 2025
$5.4B
-5.3% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025

The quarter in charts

Segment mix

Business-unit revenue, as stated

02.557.5$6.9BGrowth Portfolio$5.4BLegacy Portfolio$3.9BInternational

Segment revenue figures as stated in the event record.

Headline figures

MetricQ3 2025Prior qtrYear ago
Revenue3%$12.3 billion—
Total revenue$12,222$12.3 billion—
EPS81 %——
Growth Portfolio revenue$6.9 billion$6.6 billion—
Legacy Portfolio revenue$5.4 billion$5.7 billion—
International revenue$3.9 billion$3.8 billion—
Gross margin71.9%73.2%—

EX-99 · Oct 30, 2025

Guidance · company-stated

Direction: Raised

Revenue$46.5 billion

“5 Financial Guidance Bristol Myers Squibb is increasing its full-year 2025 non-GAAP revenue guidance from a range of approximately $46.5 billion to $47.5 billion, to a range of approximately $47.5 billion to $48.0 billion.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Margin

Gross margin71.9%

Capital allocation

(b) Includes amortization of purchase price adjustments to Celgene debt.

Cash includes cash, cash equivalents and marketable debt securities; 2.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

We delivered strong results this quarter as a result of continued execution across the business and ongoing Growth Portfolio momentum, said Christopher

Based on: Earnings release + Q3 2025 deck + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “5 Financial Guidance Bristol Myers Squibb is increasing its full-year 2025 non-GAAP revenue guidance from a range of approximately $46.5 billion to $47.5 billion, to a range of approximately $47.5 billion to $48.0 billion.”

Revenue — Raised (“increasing”)
“5 Financial Guidance Bristol Myers Squibb is increasing its full-year 2025 non-GAAP revenue guidance from a range of approximately $46.5 billion to $47.5 billion, to a range of approximately $47.5 billion to $48.0 billion.”

Classified from the release's primary full-year outlook statement.

Capital allocation

(b) Includes amortization of purchase price adjustments to Celgene debt.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Cash includes cash, cash equivalents and marketable debt securities; 2.

SEC original ↗Bristol Myers Squibb — Presentation / slide deck (8-K exhibit)EX-99Oct 30, 2025

Relative to the total debt level as of March 31, 2024; 3.

SEC original ↗Bristol Myers Squibb — Presentation / slide deck (8-K exhibit)EX-99Oct 30, 2025

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Financial assets and liabilities measured at fair value on a recurring basis are summarized below: June 30, 2026 December 31, 2025 Dollars in millions Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Cash and cash equivalents Money market and other securities $ $ 6,175 $ $ $ 6,891 $ Marketable debt securities Certificates of deposit 2,193 350 Corporate debt securities 414 439 U.

SEC original ↗Bristol Myers Squibb — 10-Q Quarterly report10-QJul 30, 2026

Marketable Debt Securities The amortized cost for marketable debt securities approximates its fair value and these securities mature within five years as of June 30, 2026 and December 31, 2025.

SEC original ↗Bristol Myers Squibb — 10-Q Quarterly report10-QJul 30, 2026

BMS also enters into cross-currency swap contracts to hedge exposure to foreign currency exchange rate risk associated with its long-term debt denominated in euros.

SEC original ↗Bristol Myers Squibb — 10-Q Quarterly report10-QJul 30, 2026

Strategy & priorities

We're focused on building for the future by accelerating innovation, advancing our pipeline, staying agile and delivering more transformational medicines to more patients.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Selling, general and administrative expenses of $1.8 billion decreased 10% on a GAAP and non-GAAP basis, primarily driven by our ongoing strategic productivity initiative.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Non-GAAP research and development expenses of $2.4 billion increased 3%, primarily due to the impact of recent acquisitions, partially offset by our ongoing strategic productivity initiative.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

The preliminary Phase 1 safety and efficacy results are consistent with the potential for immune reset, showing robust CAR T cell expansion, complete B cell depletion and re-emergence of a naive B cell phenotype across all three cohorts.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Sotyktu September 25 Announced an expansion of the company's direct-to-patient offerings, providing eligible U.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Risks & headwinds

The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Forward-looking statements are based on current expectations and projections about the company s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond the company s control and could cause the company s future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Forward-looking statements in this earnings release should be evaluated together with the many risks and uncertainties that affect the company s business and market, particularly those identified in the cautionary statement and risk factors discussion in the company s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the company s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Legal Proceedings 44 Item 1A.

SEC original ↗Bristol Myers Squibb — 10-Q Quarterly report10-QJul 30, 2026

What changed vs prior quarter

Guidance direction — prior quarter: Raised; this quarter: Raised

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Total revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Bristol Myers Squibb — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Documents

Earnings deck slides

0 decks with slide view

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Bristol Myers Squibb — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

64 documents

Earnings releases

24 documents

Presentations

24 documents

Transcripts

0 documents

No transcripts for Bristol Myers Squibb are held in this edition of the library.

Mentioned by

6 companies

Other tracked companies whose held documents mention Bristol Myers Squibb by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.